BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 16, 2011
 |  BioCentury  |  Product Development

Stemming Stroke's Effects

SanBio, ReNeuron advance stem cells into clinic for stable stroke

Stroke has been a notoriously difficult condition to treat, but SanBio Co. Ltd. and ReNeuron Group plc think stem cell therapies can reverse the symptoms of disabled patients many months after the event. The companies have competing products in Phase I testing to teat stable stroke, but see plenty of room on the market for both.

Stroke results in a pattern of rising and falling inflammation in the brain that can persist for two months or more, according to SanBio CEO Keita Mori. The challenge, he said, would be to demonstrate that stem cells might work in this window because residual inflammation would make function endpoints "moving targets."

Rather than trying to treat patients during this period of fluctuating inflammation, SanBio and ReNeuron are focused on stable stroke patients, who are typically handicapped and have a poor quality of life. Mori said about one-third of stroke patients die, one-third recover naturally, and one-third stabilize with disabilities within about six months.

Both companies are moving forward with this approach in the clinic after having shown their products can reverse functional deficits associated with stroke disability in animal models of stable stroke.

Read the full 939 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >